1. Home
  2. COGT vs SLRC Comparison

COGT vs SLRC Comparison

Compare COGT & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • SLRC
  • Stock Information
  • Founded
  • COGT 2014
  • SLRC 2007
  • Country
  • COGT United States
  • SLRC United States
  • Employees
  • COGT N/A
  • SLRC N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • SLRC Finance/Investors Services
  • Sector
  • COGT Health Care
  • SLRC Finance
  • Exchange
  • COGT Nasdaq
  • SLRC Nasdaq
  • Market Cap
  • COGT 806.1M
  • SLRC 889.2M
  • IPO Year
  • COGT 2018
  • SLRC 2010
  • Fundamental
  • Price
  • COGT $7.41
  • SLRC $16.10
  • Analyst Decision
  • COGT Buy
  • SLRC Hold
  • Analyst Count
  • COGT 6
  • SLRC 6
  • Target Price
  • COGT $15.20
  • SLRC $15.79
  • AVG Volume (30 Days)
  • COGT 2.4M
  • SLRC 220.2K
  • Earning Date
  • COGT 08-05-2025
  • SLRC 08-05-2025
  • Dividend Yield
  • COGT N/A
  • SLRC 10.19%
  • EPS Growth
  • COGT N/A
  • SLRC N/A
  • EPS
  • COGT N/A
  • SLRC 1.61
  • Revenue
  • COGT N/A
  • SLRC $227,510,000.00
  • Revenue This Year
  • COGT N/A
  • SLRC N/A
  • Revenue Next Year
  • COGT N/A
  • SLRC N/A
  • P/E Ratio
  • COGT N/A
  • SLRC $10.00
  • Revenue Growth
  • COGT N/A
  • SLRC N/A
  • 52 Week Low
  • COGT $3.72
  • SLRC $13.64
  • 52 Week High
  • COGT $12.61
  • SLRC $17.94
  • Technical
  • Relative Strength Index (RSI)
  • COGT 64.24
  • SLRC 43.96
  • Support Level
  • COGT $7.07
  • SLRC $15.80
  • Resistance Level
  • COGT $7.50
  • SLRC $16.34
  • Average True Range (ATR)
  • COGT 0.43
  • SLRC 0.27
  • MACD
  • COGT -0.06
  • SLRC -0.04
  • Stochastic Oscillator
  • COGT 55.94
  • SLRC 24.39

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

Share on Social Networks: